SILVER SPRING, Md., Dec. 18, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host...
Hence then, the article about fda approves first mesenchymal stromal cell therapy to treat steroid refractory acute graft versus host disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease )
Also on site :
- 1993 Michael Jackson Song, Once Ranked Among the ‘Worst Music Videos,’ Featured One of Hollywood's Biggest Stars
- Amy Schumer Shares Bikini Photos After 50-Pound Weight Loss— ‘Never Knew There Would Be Days Like This’
- Welcome to the mega-war: Mideast and European conflicts merge, sucking in more countries along the way—even ones claiming neutrality